In terms of provisions of Regulation 30 (read with Part A of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), this ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories' board, meeting on 16th May 2025, approved the audited standalone financial results for the quarter and year ended 31st March 2025. Revenue from operations fell to ₹652.77 lakhs in FY25 from ₹702.96 lakhs in FY24, a decline of about 7%. Net profit for the year edged up marginally to ₹49.66 lakhs from ₹48.67 lakhs, with EPS of ₹1.97 (vs ₹1.93). Statutory auditors Vora & Associates issued an unqualified (unmodified) opinion on the results. The board also approved the appointment of an Additional Director to hold office until the next AGM. Notably, operating cash flow turned sharply negative at -₹145.37 lakhs versus +₹103.47 lakhs last year, largely due to a spike in other current assets.
Mixed signals for shareholders: revenue continues to shrink year-on-year, but profits held steady, and the clean audit opinion is a positive. However, the sharp swing to negative operating cash flow and the dip in revenue may concern investors looking at underlying business momentum and liquidity.